SPECIALISED Therapeutics Asia has launched an early access program for Australian patients to receive neratinib, an extended adjuvant treatment for early-stage HER2-positive breast cancer.
The Special Access Program covers patients with special clinical needs that cannot be met by currently approved and available medicines, with the move following the signing of a licence agreement with Puma Biotechnology which gives Specialised Therapeutics exclusive rights to commercialise neratinib in Australia, NZ and South East Asia.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Apr 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Apr 18
